Financials
Faron 2024 Half-Year Financial Results | Aug. 27, 2024 |
Faron´s Annual Report 2023 | Mar. 26, 2024 |
Financial Statement January 1 to December 31 2023 | Mar. 13, 2024 |
Faron 2023 Half-Year Financial Results | Aug. 29, 2023 |
Faron´s Annual Report 2022 Published | Mar. 03, 2023 |
Financial Statement January 1 to December 31 2022 | Mar. 03, 2023 |
Faron Reports 2022 Half-Year Financial Results | Aug. 25, 2022 |
Proxies
Results of the Annual General Meeting | Apr. 05, 2024 |
Notice of Annual General Meeting 2024 | Mar. 13, 2024 |
Results of AGM | Mar. 24, 2023 |
Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 03, 2023 |
Results of AGM | Apr. 22, 2022 |
Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 25, 2022 |
Result of AGM | Apr. 23, 2021 |
Ownership Update
Grant of options | Aug. 30, 2024 |
Grant of options | Aug. 07, 2024 |
Holding(s) in Company - Replacement | Jun. 25, 2024 |
Announcement of Placing | Apr. 04, 2024 |
Grant of options | Dec. 04, 2023 |
Manager's transactions | Oct. 27, 2023 |
Exercise of options | Aug. 31, 2023 |
Announcements
FDA Grants Fast Track Designation for Bexmarilimab | Aug. 27, 2024 |
Notice of Half-Year Financial Results | Aug. 20, 2024 |
Traumakine Research Collaboration and DoD Grant | Aug. 13, 2024 |
Appointment of Chief Financial Officer | Aug. 08, 2024 |
Faron Appoints Dr. Petri Bono as new CMO | Aug. 06, 2024 |
Faron Announces Positive FDA Feedback | Jul. 11, 2024 |
Update on settlement | Jun. 25, 2024 |